Experimental evidence of electroacupuncture in ALS mouse models: a systematic review and meta-analysis - Report - MDSpire

Experimental evidence of electroacupuncture in ALS mouse models: a systematic review and meta-analysis

  • By

  • Mengwan Hu

  • Lei You

  • Xuezhuo Zhang

  • Zhibo Xuan

  • Sijia Ma

  • Xian Wu

  • July 1, 2026

  • 0 min

Share

Clinical Report: Systematic Review and Meta-Analysis of Electroacupuncture's Effects in Mouse Models of Amyotrophic Lateral Sclerosis

Overview

This systematic review and meta-analysis evaluated the efficacy of electroacupuncture (EA) in mouse models of amyotrophic lateral sclerosis (ALS), revealing significant improvements in motor function and neuroprotection.

Background

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that leads to the loss of motor neurons, resulting in severe disability and high healthcare costs. Current therapies offer limited efficacy.

Data Highlights

OutcomeEffect SizeConfidence Intervalp-value
Rotarod Test ScoreSMD = 3.3195% CI (2.05, 4.57)p < 0.001

Key Findings

  • Seventeen studies involving 372 animals were included in the analysis.
  • EA significantly improved motor function in ALS mice as measured by the rotarod test.
  • EA intervention alleviated neuroinflammation and promoted neuronal survival.
  • Improved axonal regeneration and stabilization of RNA metabolism were observed with EA treatment.
  • EA slowed disease progression and prolonged survival time in ALS models.
  • Potential publication bias was detected.

Clinical Implications

Further clinical trials are warranted to explore the efficacy of electroacupuncture in human populations.

Conclusion

This meta-analysis provides evidence for the neuroprotective effects of electroacupuncture in preclinical ALS models.

Related Resources & Content

  1. Frontiers in Neurology, 2026 -- Acupuncture therapy for post-stroke spasticity: a systematic review and exploratory network meta-analysis of clinical efficacy and dose–response relationship
  2. Frontiers in Neurology, 2026 -- Electroacupuncture Improves Upper-Limb Motor Function and Modulates Sensorimotor Network Connectivity in Subacute Stroke: A Randomized Controlled Trial
  3. Frontiers in Neurology, 2026 -- A network meta-analysis of the performance of acupoint stimulation therapy in improving fatigue, neurological function, and activities of daily living in patients with multiple sclerosis
  4. European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERN EURO‐NMD) - PMC
  5. Overview | Motor neurone disease: assessment and management | Guidance | NICE
  6. Retirement of Guidelines: Practice Parameter Update: The Care of the Patient With Amyotrophic Lateral Sclerosis: Drug, Nutritional, and Respiratory Therapies (An Evidence-Based Review) | Neurology
  7. FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene | FDA
  8. Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS | Amylyx Pharmaceuticals, Inc.
  9. Real-world safety and tolerability of intravenous edaravone in patients with amyotrophic lateral sclerosis - PMC
  10. Frontiers | Current state of research on acupuncture for the treatment of amyotrophic lateral sclerosis: A scoping review
  11. Exploring the Role of Metformin in Spinal Cord Injury Treatment: A Systematic Review and Meta-Analysis of Effects on Locomotor Function, Neuropathic Pain Relief, and Secondary Injury Mechanisms
  12. European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERN EURO‐NMD) - PMC
  13. Overview | Motor neurone disease: assessment and management | Guidance | NICE
  14. Retirement of Guidelines: Practice Parameter Update: The Care of the Patient With Amyotrophic Lateral Sclerosis: Drug, Nutritional, and Respiratory Therapies (An Evidence-Based Review) | Neurology
  15. FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene | FDA
  16. Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS | Amylyx Pharmaceuticals, Inc.
  17. Real-world safety and tolerability of intravenous edaravone in patients with amyotrophic lateral sclerosis - PMC
  18. Frontiers | Current state of research on acupuncture for the treatment of amyotrophic lateral sclerosis: A scoping review

Original Source(s)

Related Content